These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30111966)

  • 41. Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
    Gotfrit J; Shin JJW; Mallick R; Stewart DJ; Wheatley-Price P
    Oncologist; 2020 Jan; 25(1):e130-e137. PubMed ID: 31506392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. From equal access to health care to equitable access to health: a review of Canadian provincial health commissions and reports.
    Mhatre SL; Deber RB
    Int J Health Serv; 1992; 22(4):645-68. PubMed ID: 1399174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Portrait of rural emergency departments in Québec and utilization of the provincial emergency department management Guide: cross sectional survey.
    Fleet R; Poitras J; Archambault P; Tounkara FK; Chauny JM; Ouimet M; Gauthier J; Dupuis G; Tanguay A; Lévesque JF; Simard-Racine G; Haggerty J; Légaré F
    BMC Health Serv Res; 2015 Dec; 15():572. PubMed ID: 26700302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
    Morrell L; Wordsworth S; Fu H; Rees S; Barker R
    BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Oncology Drug Review Times on Public Funding Recommendations.
    Hussain M; Wong C; Taguedong E; Verma S; Mahsin M; Karim S; Lee-Ying R; Ezeife DA
    Curr Oncol; 2023 Aug; 30(8):7706-7712. PubMed ID: 37623039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Service use for mental health reasons: cross-provincial differences in rates, determinants, and equity of access.
    Vasiliadis HM; Lesage A; Adair C; Boyer R
    Can J Psychiatry; 2005 Sep; 50(10):614-9. PubMed ID: 16276852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Pathway for New Cancer Drug Access in Canada.
    Gotfrit J; Dempster W; Chambers J; Wheatley-Price P
    Curr Oncol; 2022 Jan; 29(2):455-464. PubMed ID: 35200541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group.
    MacLean DR; Petrasovits A; Nargundkar M; Connelly PW; MacLeod E; Edwards A; Hessel P
    CMAJ; 1992 Jun; 146(11):1969-74. PubMed ID: 1596846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.
    Leung L; de Lemos ML; Kovacic L
    J Oncol Pharm Pract; 2018 Dec; 24(8):584-598. PubMed ID: 28747103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Access to expensive anti-cancer drugs.
    Mileshkin L; Sullivan D
    J Law Med; 2011 Dec; 19(2):232-43. PubMed ID: 22319998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of health leadership and management capacity in the Solomon Islands.
    Asante A; Roberts G; Hall J
    Pac Health Dialog; 2012 Apr; 18(1):166-77. PubMed ID: 23240354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Canada Pension Plan's experience with investing its portfolio in equities.
    Sarney M; Preneta AM
    Soc Secur Bull; 2001-2002; 64(2):46-56. PubMed ID: 12428509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.
    Bentley C; Costa S; Burgess MM; Regier D; McTaggart-Cowan H; Peacock SJ
    BMC Health Serv Res; 2018 May; 18(1):339. PubMed ID: 29739463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.